Quotient Sciences and CPI Launch Joint Venture to Accelerate RNA Drug Development

Quotient Sciences and CPI have announced a strategic partnership to create a joint venture aimed at accelerating the development of mRNA-based drugs from the lab to the clinic. The collaboration integrates Quotient’s Translational Pharmaceutics platform with CPI’s expertise in RNA synthesis and lipid nanoparticle (LNP) encapsulation, offering a streamlined pathway for mRNA therapeutics.

A New Model for mRNA Development

By uniting their capabilities, the venture will provide a first-of-its-kind solution for mRNA drug product development. The platform includes mRNA synthesis, LNP formulation, clinical manufacturing, and early-phase testing, enabling developers to go from plasmid to clinical dose in as little as two months, dramatically shortening traditional timelines.

Impact on Biopharma Innovation

The approach allows real-time dose and formulation adjustments during clinical studies, improving flexibility and potentially boosting patient outcomes in delivery-sensitive modalities. This collaboration positions Quotient Sciences and CPI at the forefront of RNA innovation, offering developers a powerful new model to accelerate next-generation therapies.